BioMarin Pharmaceutical Inc. (BMRN)

Market Cap	12.09B -1.2%
Revenue (ttm)	3.09B +12.4%
Net Income	520.42M +61.5%
EPS	2.68 +59.5%
Shares Out	192.11M
PE Ratio	23.47
Forward PE	13.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,738,649
Open	64.08
Previous Close	64.08
Day's Range	62.63 - 65.95
52-Week Range	50.76 - 73.51
Beta	0.26
Analysts	Buy
Price Target	88.94 (+41.35%)
Earnings Date	Feb 23, 2026

About BMRN

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 1999
• Employees: 3,040
• Stock Exchange: NASDAQ
• Ticker Symbol: BMRN
• Website: https://www.biomarin.com

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Analyst Summary

According to 16 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price target is $88.94, which is an increase of 41.35% from the latest price.

Price Target

$88.94

(41.35% upside)

Analyst Consensus: Buy